Alzheimer’s Association International Conference 2026 (AAIC 2026)

Treatment with donanemab continues to show increasing clinical benefits in patients with early symptomatic Alzheimer’s disease (AD), according to the phase III TRAILBLAZER‐ALZ 2 long-term extension (LTE) study presented at AAIC 2026.

A multidomain, systematic lifestyle intervention (SLI) may yield a significantly greater improvement in global cognitive function over 2 years compared with a flexible lifestyle intervention (FLI) among older adults at high risk of dementia, according to the LatAm-FINGERS* trial presented at AAIC 2026.

In the phase II CELIA trial, the investigational tau-targeting antisense oligonucleotide (ASO) diranersen has shown therapeutic potential in patients with early Alzheimer’s disease (AD), yielding substantial reductions in tau burden and slowing clinical decline despite missing its primary endpoint.

The experimental combination of tetrahydrocannabinol (THC) plus cannabidiol (CBD) proves beneficial in reducing agitation in hospice care-eligible patients with late-stage dementia, according to the phase II LiBBY trial.

A pooled analysis presented at AAIC^® 2026 demonstrated a consistent association between higher levels of plasma phosphorylated tau 217 (p-tau217) and an increased risk of clinical progression and accelerated cognitive decline in a large cohort of older adults without cognitive impairment.